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Abstract
Background: Aberrant expression of cyclin-dependent protein kinases (CDK) is a hallmark of cancer. CDK11 plays a
crucial role in cancer cell growth and proliferation. However, the molecular mechanisms of CDK11 and CDK11
transcriptionally regulated genes are largely unknown.
Methods: In this study, we performed a global transcriptional analysis using gene array technology to investigate
the transcriptional role of CDK11 in osteosarcoma. The promoter luciferase assay, chromatin immunoprecipitation
assay, and Gel Shift assay were used to identify direct transcriptional targets of CDK11. Clinical relevance and
function of core-binding factor subunit beta (CBFβ) were further accessed in osteosarcoma.
Results: We identified a transcriptional role of protein-DNA interaction for CDK11p110, but not CDK11p58, in the
regulation of CBFβ expression in osteosarcoma cells. The CBFβ promoter luciferase assay, chromatin
immunoprecipitation assay, and Gel Shift assay confirmed that CBFβ is a direct transcriptional target of CDK11. High
expression of CBFβ is associated with poor outcome in osteosarcoma patients. Expression of CBFβ contributes to
the proliferation and metastatic behavior of osteosarcoma cells.
Conclusions: These data establish CBFβ as a mediator of CDK11p110 dependent oncogenesis and suggest that
targeting the CDK11- CBFβ pathway may be a promising therapeutic strategy for osteosarcoma treatment.
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Background
It has been well established that overexpression and acti-
vation of cyclin-dependent kinases (CDK) is a hallmark
of human cancer [1, 2]. The Food and Drug Administra-
tion (FDA) has approved the CDK4/6 inhibitors Palboci-
clib, Ribociclib and Abemaciclib for treating metastatic
breast cancer. These inhibitors have also demonstrated
promising antitumor potentials both as a monotherapy
and in combined therapy in numerous clinical trials [3–6].
CDK11 is a member of the serine/threonine protein kin-
ase family. CDK11 plays a crucial role in cell proliferation
and growth of cancers, such as breast cancer, ovarian
cancer, multiple myeloma, and sarcoma [7–12]. Knock-
down of CDK11 by shRNA or siRNA inhibits cancer cell
growth and induces apoptosis. In vivo administration of
CDK11 siRNA was shown to reduce tumor growth in can-
cer xenograft mouse models [13, 14]. Importantly, nuclear
CDK11 expression levels correlate with clinical prognosis
in cancer patients, including breast cancer, ovarian cancer,
and sarcoma [8–10, 13–15]. Downregulation of CDK11
also causes significant loss of cell viability and clonal sur-
vival in breast cancer, colon cancer, cervical cancer, mul-
tiple myeloma, and acute myeloid leukemia [9, 16–19].
There are three major CDK11 protein isoforms encoded
from an identical mRNA: CDK11p110, CDK11p58, and
CDK11p46. The CDK11p58 isoform is generated by an in-
ternal ribosome entry site sequence (IRES) in the same
mRNA encoding the CDK11p110 isoform. CDK11p46 is
generated by caspase dependent cleavage of CDK11p110
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and CDK11p58 [20, 21]. In general, these protein iso-
forms regulate RNA transcription and processing, mi-
tosis, and apoptosis. CDK11p110 is expressed in all
phases of the cell cycle, while CDK11p58 is expressed
transiently only during the G2/M phase of mitosis.
Inhibition of CDK11 specifically suppresses RNAP II-
dependent transcription and can be rescued by addition
of purified CDK11 [22]. However, the molecular mech-
anisms and signaling pathways of CDK11 regulated
genes in cancer cells are largely unknown.
In the present study, we performed a global transcrip-
tional analysis using gene array technology to investigate
the transcriptional role of CDK11 in osteosarcoma. We
identified CDK11p110, but not CDK11p58, in the transcrip-
tional regulation of core-binding factor subunit beta (CBFβ)
expression in osteosarcoma cells, which is important for
bone cell development and formation of the skeleton.
Knockdown of CDK11 caused a strong decrease in the
levels of CBFβ. High CBFβ expression correlated with
CDK11 expression and contributed to reduced overall
survival in osteosarcoma patients. Our data suggest that a
direct link exists between the CDK11p110- CBFβ pathway
and osteosarcoma cell growth and migration.
Methods
Cell lines
The human osteosarcoma cell lines U-2OS, MG63,
SaOS, MNNG/HOS, and 143B were purchased from the
American Type Culture Collection (Rockville, MD). The
human osteosarcoma KHOS cell line was kindly pro-
vided by Dr. Efstathios Gonos (Institute of Biological
Research & Biotechnology, Athens, Greece). The human
osteoblast cells NHOst and HOBc were purchased from
LonzaWallkersville (Walkersville, MD) and PromoCell
GmbH (Heidelberg, Germany), respectively. The osteo-
sarcoma cell lines were incubated in RPMI 1640 (Life
Technologies, Grand Island, NY) supplemented with
10% fetal bovine serum. The osteoblast cell lines were
cultured in osteoblast growth medium (PromoCell) with
10% fetal bovine serum.
Synthetic CDK11 or CBFβ siRNA transfection
Validation of CDK11 or CBFβ knockdown phenotypes in
osteosarcoma cell lines was conducted by transfection of
synthetic human CDK11 (Applied Biosystems, Grand
Island, NY) or CBFβ siRNA (Applied Biosystems). The
siRNA sequence targeting CDK11 corresponded to coding
regions (5′-AGAUCUACAUCGUGAUGAAtt-3′, anti-
sense 5′-UUCAUCACGAUGUAGAUCUtg-3′) of the
CDK11 gene. The siRNA sequence targeting CBFβ
corresponded to coding regions (5′-CCGAGAGUAU
GUCGACUUATT-3′, antisense 5′- UAAGUCGACA
UACUCUCGGCT-3′) of the CBFβ gene. Transfection
with siRNA was performed using Lipofectamine™
RNAiMAX (Invitrogen, Grand Island, NY) according
to the manufacturer’s instructions. The non-specific
siRNA oligonucleotide (Applied Biosystems) was used
as a negative control. Medium was changed 24 h after
transfection with RPMI 1640 supplemented with 10%
fetal bovine serum. Total protein was extracted 72 h
after CDK11 or CBFβ siRNA transfection.
Global gene expression profiling and analysis
Total RNA was extracted from the cells using TRIzol re-
agent (Invitrogen, Carlsbad, CA) and submitted to Human
Genome U133 plus 2 arrays for microarray. Microarray
studies were performed on KHOS and U-2OS cells that
were transfected with CDK11 siRNA or non-specific
siRNA. To account for and eliminate biological noise, RNA
was isolated from three distinct flasks of each cell line 48 h
post siRNA transfection. Total RNA was extracted from
the cells using TRIzol reagent (Invitrogen, Carlsbad, CA)
according to manufacturer’s guidelines. The quality and
size distribution of the RNA were assessed for microarray
analysis. Each sample was separately hybridized on Human
Genome U133 plus 2 arrays, according to the manufac-
turer’s guidelines (Affymetrix, Santa Clara, CA). Raw Affy-
metrix intensity measurements were background corrected,
normalized, and summarized into gene expression mea-
surements using dChip (dchip.org; https://www.hsph.har-
vard.edu/pqg/software/). The average expression value for
each gene across the arrays was used to normalize the
mRNA intensities. The CEL files were transformed into in-
tensity information using the RMA normalization of Gene-
Sifter (http://www.genesifter.net/web/qs_analysis.html) and
Qlucore 3.0 (New York, NY), and fold change was used to
select differentially expressed genes [23–25]. Differentially
expressed gene identifiers were uploaded into a heat map.
Data are available at the database of Gene Expression
Omnibus (https://www.ncbi.nlm.nih.gov/geo/) with the
access code GSE73422 [26, 27].
Plasmid constructions
GFP-CDK11p110 and GFP-CDK11p58 plasmids were kindly
provided by Dr. Régis Giet. GFP-CDK11p110 kinase-dead
or kinase-active mutations were generated. The pEGFP-
N3 plasmid was purchased from Clontech (Mountain
View, CA) as plasmid transfection control.
Luciferase assays
The human CBFβ promoter in pLightSwith_Prom plasmid
(SwitchGear Genomics, Carlsbad, CA) encodes the wild
type promoter sequence (1 kb upstream of the CBFΒ gene
5′-UTR). CDK11p110, CDK11p58, and CDK11p110 mutant
plasmids were transfected with Lipofectamine™ 3000
(Invitrogen, Grand Island, NY). LightSwitch™ Promoter
Reporter Vector (SwitchGear Genomics) was transfected
as an internal transfection control. Cells were collected 48
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h after transfection and lysates were prepared for lucifer-
ase assays following the manufacturers’ protocols (Switch-
Gear Genomics). Luciferase activity with LightSwitch
Assay Reagents was measured by the Perkin Elmer Victor
3 Microplate Readers (Waltham, MA).
Chromatin immunoprecipitation (ChIP) assays
ChIP assays were performed with the U-2OS and KHOS
cell lines according to the manual from Cell Signaling
Technology (MA). The CBFβ promoters were amplified
using PCR. In brief, 2 × 107 cells were transfected with
CDK11 siRNA. Forty-eight hours after transfection, cells
were crosslinked in 1% formaldehyde for 10min at room
temperature. Crosslinking was terminated by incubation of
cells with glycine solution for 5min. Cells were washed and
chromatin was sonicated to a length of 100–900 bp using a
VIRSONIC 100 Ultrasonic Homogenizer (Woburn, MA),
while samples were maintained on ice at 4 °C. Protein G
Magnetic beads (SimpleChIP® Enzymatic Chromatin IP Kit
(Magnetic Beads), Cell Signaling Technology, Danvers,
MA) were washed with blocking solution and pre-coated
overnight with anti-CDK11 antibody (sc-928, Santa Cruz
Biotechnology, Santa Cruz, CA), anti-Histone H3 (Simple-
ChIP®Kit, Cell Signaling Technology) as a positive control,
or IgG as a negative control. IP samples were incubated
overnight at 4 °C with rotation. Beads were collected by
magnetic attraction using a magnetic rack. After washing,
protein-DNA complexes were eluted and crosslinks were
reversed by incubating the suspensions for 2 h at 65 °C.
DNA was purified using spin columns. ChIP DNA was ana-
lyzed with PCR using positive and negative controls. The
ChIP signal was normalized to the input sample and total
DNA content. ChIP PCR primers were designed in the
proximal regions of CBFβ gene promoters, around genomic
locations where potential CDK11-binding elements were
located. Standard PCR method was performed following
the manufacturer’s ChIP Protocol (Cell Signaling Technol-
ogy). PCR products were confirmed by sequencing and
compared with CBFβ promoters.
Western blotting assay
Total protein lysates from the osteosarcoma cells were
harvested by 1× RIPA Lysis Buffer (Upstate Biotechnology,
Charlottesville, VA) plus complete protease inhibitor
cocktail tablets (Roche Applied Science, IN, USA). Protein
Assay Reagents (Bio-Rad, CA) and a SPECTRAmax Mi-
croplate Spectrophotometer from Molecular Devices
(Sunnyvale, CA) were applied to evaluate the protein con-
centrations. The primary antibodies for CDK11 (1:1000
dilution) and β-actin (1:2000 dilution) were purchased
from Santa Cruz and Sigma-Aldrich, respectively. Sec-
ondary antibodies IRDye® 800CW or IRDye® 680LT
were purchased from LI-COR (Biosciences, NE).
Western blot analysis was performed as previously
reported (Duan et al., 2008). Membrane signals were de-
tected using the Odyssey infrared imaging system. Quanti-
fication analysis of western blot values was performed
with Odyssey software 3.0 (LI-COR Bioscience, NE).
MTT cell proliferation assay
KHOS or U-2OS cell lines were transfected with CBFβ
siRNA or non-specific siRNA. 3 × 103 cells were seeded
into each well of 96-well plates. Complete growth
medium without antibiotics was added into each well to
a volume of 100 μl in triplicate. After 72 h of incubation,
20 μl of MTT (5 mg/mL, dissolved in PBS, Sigma-
Aldrich) was added to each well and the cells were cul-
tured for 4 h at 37 °C. The MTT formazan product was
dissolved with acid isopropanol. The absorbance at a
wavelength of 490 nm (A490) was measured on a SPEC-
TRAmax Microplate Spectrophotometer from Molecular
Devices (Sunnyvale, CA). All results were analyzed by
GraphPad Prism 5 software (San Diego, CA).
Wound healing migration assay
Migration activity was detected by multiple scratch wounds
assay. In brief, 1 × 105 cells per well were plated into 12-
well plates and transfected with CBFβ siRNA. Three paral-
lel lines were made in confluent cell cultures with a 200 μl
tip. After suspended cells were washed away with serum-
free medium, the cultures were fed with complete medium
again. The wounds were observed at 0, 8, and 24 h after
wounding, and photographed via microscope (Nikon In-
struments, Inc.). Three images were taken per well at each
time point using a 10× objective, and the distance between
the two edges of the scratch (wound width) was measured
at 10 sites in each image. The cell migration distance was
defined as the wound width at the 0 h time point minus the
wound width at each time point and then divided by two.
Matrigel invasion assay
The matrigel invasion assay was performed with the BD
BioCoat™ Matrigel™ Invasion Chamber (Becton-Dickinson,
MA) following the manufacturer’s instructions. CBFβ
siRNA or non-specific siRNA transfected cells (5 × 104 cell/
plate) were seeded into the upper chamber of each well in
serum-free medium, and complete medium was put into
the bottom chamber. The invasion chamber was incubated
for 24 h at 37 °C under 5% CO2. Afterward, non-invading
cells were removed by scrubbing from the upper surface of
the membrane with cotton-tipped swabs. After washing the
cells with medium, complete medium with 1 μg/mL
Hoechst 33342 (Invitrogen) was used to stain nuclei of
invading cells for 5min. Images were acquired by a Nikon
Eclipse Ti-U fluorescence microscope and phase contrast
microscope equipped with a SPOT RT digital camera. The
number of invading cells was counted in three images per
membrane by microscopy using a 20× objective.
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Immunohistochemical staining on TMA
The expression levels of CBFβ and CDK11 were deter-
mined based on the immunohistochemistry protocol
(Paraffin) from Cell Signaling Technology (Beverly, MA)
as previously described (Zhang et al., 2013). Briefly, 5-
μm-thick array sections were baked at 60 °C for 1 h,
dewaxed with xylene (three times for 5 min each), trans-
ferred through 100% ethanol (twice for 5 min each),
rehydrated through graded alcohol, and then immersed
in deionized water for 10 min. Antigen retrieval was
processed with Target Retrieval Solution (Dako, North
America, Inc., CA). Afterward, the slide was washed with
PBS twice for 5 min. Following the process of antigen re-
trieval, endogenous peroxidase activity was quenched by
incubation in 3% hydrogen peroxide. Then, blocking so-
lution (Cell Signaling Technology) was applied for 1 h at
room temperature, and primary CBFβ or CDK11 anti-
body (1:50 dilution, in 1% bovine serum albumin PBS)
was probed at 4 °C overnight in a humidified chamber.
Each step was accompanied by three Tris-buffered saline
(TBS) rinses, and the bound antibody on the array was
detected by using SignalStain® Boost Detection Reagent
(Cell Signaling Technology) and SignalStain® DAB (Cell
Signaling Technology). Finally, sections were counter-
stained with Hematoxylin QS (VectorLaboratories) and
the slide was mounted with VectaMount AQ (Vector
Laboratories) for long-term preservation. CBFβ and
CDK11 expressions were evaluated according to visible
nuclear staining and calculated by the percentage of
positive cells among the entire spot. Thereby, CBFβ
staining patterns were categorized into 6 groups: 0, no
nuclear staining; A, 1+, < 10% of cells stained positive; B,
2+, 10 to 25% positive cells; C, 3+, 26 to 50% positive cells;
D, 4+, 51 to 75% positive cells; and E, 5+, > 75% positive
cells. CBFβ and CDK11 staining images were obtained
using a Nikon Eclipse microscope (Nikon Corp) with a
SPOT RT digital camera (Diagnostic Instruments Inc.).
Results
Expression profiling of gene regulation by CDK11
To identify the genes regulated in response to knock-
down of CDK11 expression, KHOS and U-2OS osteosar-
coma cell lines were transfected with CDK11 siRNA and
their gene expression profiles were analyzed by Genesif-
ter. The microarray data from this study has been sub-
mitted to the database of Gene Expression Omnibus
(http://www.ncbi.nlm.nih.gov/geo/) and assigned the
GEO accession number GSE73422 [26, 27]. Genome-
wide gene profiling identified 162 differentially expressed
genes (≥ 1.5 log fold alteration in expression, P < 0.05) in
both KHOS and U-2OS cell lines with CDK11 siRNA
knockdown (Fig. 1a and Additional file 2: Table S1), as
compared with non-specific siRNA treated cells or un-
treated cells. Analysis by biological category revealed
that these differentially expressed genes are enriched in
cellular processes (17%), metabolic processes (13%), and
biological regulation (10%) (Fig. 1b). Further analyses
were focused on the molecular function of these differ-
entially expressed genes. We observed that the genes in-
volved in protein or DNA binding (n = 74), enzyme
catalytic activity (n = 37), and transcription regulator ac-
tivity (n = 9) comprised the most common molecular
function categories (Fig. 1c). This indicated that CDK11
is involved in extensive biological regulation and plays
important roles in transcription regulation. Further ana-
lysis of the altered gene clusters using Qlucore software
revealed the top 20 significantly differentially expressed
genes, which are shown in a heat map as Fig. 1d and
Additional file 3: Table S2 (P < 0.05). Among these
genes, 16 were downregulated, whereas the remaining
genes were upregulated. CBFβ was the most highly
correlated expressing gene with CDK11.
CBFβ expression depends on CDK11 expression on
transcriptional and translational levels
The relationship between CDK11 and CBFβ was evaluated
in KHOS and U-2OS cell lines using quantitative RT-
PCR. We observed knockdown of CDK11 significantly
decreased transcript levels four-fold and five-fold in
KHOS and U-2OS cell lines (Fig. 2a). In accordance with
decreasing CDK11 mRNA, there was a three-fold decrease
in CBFβ mRNA expression compared with controls in
both KHOS and U-2OS cell lines (Fig. 2a). To investigate
whether the downregulation in expression observed at the
mRNA level was also reflected at the protein level, cells
were transfected with increasing doses of CDK11 siRNA.
CDK11 protein expression was suppressed by CDK11
siRNA in a dose-dependent manner, while CBFβ protein
was also reduced in a dose-dependent manner (Fig. 2b).
These results demonstrated that CBFβ expression depends
on CDK11 expression at the translational level. In normal
human cells, the expression of CDK11 is tightly regulated;
for example, in the normal human osteoblast cell lines
HOBc and NHOst, there are extremely low or almost
undetectable levels of CDK11, while CBFβ levels are cor-
respondingly low in normal human osteoblast cell lines
and exhibit high expression in osteosarcoma cell lines
(Fig. 2c). MNNH/HOS and 143B are osteosarcoma cell
lines that are highly tumorigenic and are able to induce
pulmonary metastases in xenograft mouse models in vivo
[28, 29]. Interestingly, CDK11 expressions in MNNH/
HOS and 143B cell lines were higher than in U-2OS and
KHOS cell lines. Consistent with this, the protein expres-
sions of CBFβ were also higher in the MNNH/HOS and
143B cell lines than the non-metastatic osteosarcoma U-
2OS and KHOS cell lines (Fig. 2d). Four out of eight
osteosarcoma tissue samples showed that both CBFβ and
CDK11 proteins were highly expressed (Fig. 2E).
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CDK11p110 localizes to the nucleus and is required for the
transcriptional regulation of CBFβ genes
The human CDK11 gene is located on chromosome
1p36.33 and contains 20 exons and 19 introns (Fig. 3a).
To determine whether CDK11p58, CDK11p110, or both
isoforms are associated with transcription, we first ex-
amined the subcellular localization of these two iso-
forms. Transfection with different CDK11 isomers fused
with GFP expression vectors revealed that CDK11p110
was localized in the nucleus of three different osteosar-
coma cell lines, while CDK11p58 was mainly localized in
the cytoplasm (Fig. 3b). We then generated a U-2OS cell
line stably expressing the GFP-CDK11p58 or the GFP-
CDK11p110 protein (Fig. 3c). Consistent with transient
transfection, the selected U-2OS- GFP-CDK11p110 cell
line showed nuclear localization (Fig. 3c). Also as
expected, the selected U-2OS-GFP-CDK11p58 cell line
localized largely in the cytoplasm. Moreover, CDK11p110
was highly and constantly expressed in U-2OS and KHOS
cell lines, whereas CDK11p58 was almost undetectable in
these cells (Fig. 3d). Previous studies have shown that
CDK11p110 protein is mainly localized in the nucleus of
osteosarcoma cells both in cell lines and in tumor tissues
[13]. Similar cellular localization of CDK11p110 has been
demonstrated in other types of cancer cells, including
in breast cancer and ovarian cancer [8, 9, 14]. Because
CDK11p110 has been found broadly distributed onto
chromatin and is involved in some aspects of transcrip-
tion [20, 22], we investigated whether CBFβ was regu-
lated by CDK11p110 or by CDK11p58.
We measured the regulatory activity of CDK11 on the
CBFβ promoter using luciferase reporter assays. The
length of the CBFΒ promoter region was 1062 nucleic acid
base pairs (bp) from − 760 to + 302 relative to the tran-
scriptional start site. To study how CDK11 regulates CBFβ
expression, a DNA fragment containing this region was
Fig. 1 Global gene expression profiling reveals gene regulation in response to CDK11 knockdown. a Venn diagram of genes overexpressed and
underexpressed in CDK11 siRNA treated cells compared with control group. Genes overexpressed/underexpressed in two cell lines are indicated
in the overlapping regions of the circles. b Differentially expressed genes from gene expression profiling were grouped by biological process; the
percentages of genes that are involved in each particular biological process are shown. c Distribution of molecular function was determined by
differentially expressed genes (over 1.5-fold). d Heat map of significantly regulated genes in U-2OS and KHOS cell lines transfected with CDK11
siRNA. The genes listed in the hierarchical clustering represent the average log2 fold change
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inserted upstream of the RenSP luciferase gene in the
LightSwitch Promoter Reporter vector; once protein is
bound to the CBFβ promoter region, it activates or en-
hances the luciferase activity (Fig. 4a). Transient transfec-
tion assays were conducted in KHOS and U-2OS cell
lines. Co-expression of the CBFβ promoter luciferase
vector with CDK11p110 increased luciferase activity seven-
fold and six-fold in U-2OS and KHOS cells, respectively
(Fig. 4b and c). Furthermore, CDK11p110 induced CBFβ
promoter activity in a dose-dependent manner in
both of the osteosarcoma cell lines. These results sug-
gest that CDK11p110 acts as a transcriptional activator
on the CBFβ promoter in these cell lines. We then
investigated whether CDK11p58 was also involved in
CBFβ regulation. As shown in Fig. 4d, in the presence
of the CDK11p110 expression plasmid, CBFβ promoter
activity was dramatically increased. However, the
CDK11p58 expression vector had almost no effect on
CBFβ promoter activity in the KHOS cell line. Similar
to the KHOS cell line, CDK11p58 expression also
showed no significant effect on CBFβ promoter activ-
ity in the U-2OS cell line (Fig. 4e). These data imply
that CDK11p110, but not CDK11p58, increases CBFβ
transcriptional activity.
CDK11p110 directly upregulates CBFβ expression by
binding to the CBFβ promoter
DNA-protein interactions are crucial to fundamental
cellular events, including gene transcription. Thus, these
studies hold the key to our understanding of mecha-
nisms underlying deregulated gene expression in human
diseases, such as in cancer. The luciferase assay showed
Fig. 2 CBFβ expression depends on CDK11 expression on transcriptional and translational levels. a Verification of the altered gene expression
observed in the gene array for selected genes, including CBFβ and CDK11, using quantitative RT-PCR. Two different cell lines (KHOS and U-2OS)
were analyzed, expression was normalized using the KHOS or U-2OS untreated control, and results were depicted as relative expression in these
cells. b CDK11 siRNA downregulated the expression of CDK11 and CBFβ in a dose-dependent manner. KHOS or U-2OS cells were transfected
with CDK11 siRNA with increasing concentrations. The protein expression of CBFβ decreased dependently with CDK11 expression. c Expressions
of CDK11 and CBFβ in osteosarcoma cell lines and in normal osteoblast cell lines. d Expressions of CDK11 and CBFβ in osteosarcoma cell lines
and metastatic cell lines. e Expressions of CDK11 and CBFβ in osteosarcoma tissues. *P < 0.05
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that CDK11p110 regulates the CBFβ promoter. However,
whether this regulation was induced by CDK11p110
directly binding to the CBFβ promoter or not re-
mains unclear. In order to identify the direct inter-
action between CDK11p110 and CBFβ, the chromatin
immunoprecipitation (ChIP) assay was applied. The
ChIP assay is a powerful method to study interac-
tions between proteins and a specific genomic DNA
region (protein-DNA interaction). Recruitment of
proteins to promoters of specific genes is a common
mechanism to activate or enhance gene transcription
[30]. In the ChIP assay, the level of enrichment of
the DNA sequence is determined relative to the total
amount of input DNA (2% of input) (Additional file 1:
Figure S1). To determine which site(s) might bind
with the CDK11p110 protein, we designed four pairs
of primers whose corresponding regions almost
cover the whole length of the CBFβ promoter (− 680
to 287 bp) (Fig. 5a). Of the four pairs of primers,
significant enhancement of CDK11p110 binding was
observed by ChIP in Primer 3 (− 436/− 227) and Pri-
mer 4 (− 680/− 547) (Fig. 5a). Consistently, knock-
down of CDK11p110 by siRNA significantly decreased
the binding efficiency of the CBFΒ promoter region
with Primer 3 (Fig. 5b). Sequencing of Primer 3
ChIP products confirmed that binding area located
at the CBFβ promoter area in the genome (data were
not shown). These data support an important role
for CDK11p110 in mediating CBFβ expression in
osteosarcoma through its ability to directly bind to
the two unique sites of DNA sequences in the CBFβ
promoter.
Fig. 3 CDK11p110 localizes to the nucleus and exhibits high expression in tumor cells. a Schematic showing CDK11 chromosome exon locations,
specifically the translated site that codes two protein isoforms. The CDK11p58 isoform is generated by an internal ribosome entry site sequence
(IRES) in the same mRNA encoding the CDK11p110 isoform. b GFP-CDK11p110 and GFP-CDK11p58 transient transfection revealed that CDK11p110 is
localized only in the nucleus, while CDK11p58 is expressed in the cytoplasm in three different cell lines (original magnification, 200×). c U-2OS-
GFP-CDK11p110 and U-2OS- GFP-CDK11p58 selective stable cell lines show that CDK11p110 is localized only in the nucleus, while CDK11p58 is
mainly expressed in the cytoplasm (original magnification, 200×). d CDK11p110 is highly expressed in U-2OS and KHOS cell lines; on the contrary,
CDK11p58 is almost undetectable in these cell lines
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CBFβ contributes to the proliferation and metastatic
behavior of osteosarcoma cells
CDK11 plays a crucial role in cancer cell proliferation and
growth, including in osteosarcoma. The current study has
found that CDK11 protein can directly regulate CBFβ ex-
pression. Although CBFβ has been reported to play im-
portant roles during skeletal development in previous
studies, the role of CBFβ in osteosarcoma are remains
Fig. 4 CDK11p110, not CDK11p58, regulates promoter activity of CBFβ genes. a Schematic representation of the promoter-luciferase construct showing
the CBFβ promoter region. b CDK11 p110 upregulates CBFβ promoter-luciferase in a dose-dependent manner in the U-2OS cell line. U-2OS cells were
transfected with the CBFβ promoter-luciferase construct. Co-expression was conducted with an empty expression vector (control) or CDK11 expression
vectors. Error bars indicate standard deviation and are from at least three replicates. c CDK11p110 upregulates CBFβ promoter-luciferase in a dose-
dependent manner in the KHOS cell line. KHOS cells were transfected with the CBFβ promoter-luciferase construct. Co-expression was conducted with
an empty expression vector (control) or CDK11 expression vectors. Error bars indicate standard deviation and are from at least three replicates. d
CDK11p110, not CDK11p58, activates the CBFβ promoter-luciferase in the KHOS cell line. e CDK11p110 significantly increases CBFβ promoter-luciferase in
KHOS cell line. f Schematic showing major structural features of the CDK11p110 protein. CDK11p110 kinase-dead or kinase-active mutations were
generated. The asterisk represents the amino acid that was mutated to create kinase-dead or active mutations. g In the U-2OS cell line, the C-terminal
kinase domain mutation of CDK11p110 failed to affect CDK11p110-mediated CBFβ activation. h The C-terminal kinase domain mutation of CDK11p110
also did not change CBFβ promoter activity in the KHOS cell line. *P < 0.05., **P < 0.01
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unknown. Therefore, we further investigated the functional
role of CBFβ in osteosarcoma. Western blotting of cells
with CBFΒ siRNA demonstrated that CBFβ expression can
be inhibited in a dose-dependent manner (Fig. 6a). Deple-
tion of CBFβ by siRNA resulted in dose-dependent cell
growth inhibition in both KHOS and U-2OS cell lines,
which was not observed with non-specific siRNA transfec-
tion (Fig. 6b to e). Since CBFβ showed higher expression in
metastasis cell lines MNNH/HOS and 143B as compared
with non-metastatic cell lines U-2OS and KHOS, we exam-
ined whether CBFβ knockdown by siRNA transfection
could affect the migratory and invasive activities of osteo-
sarcoma cells by wound healing assay and Matrigel invasion
assay. The migration assay showed that downregulation of
CBFβ significantly suppressed the migration of U-2OS and
KHOS cells (Fig. 6f and g). Consistently, Matrigel invasion
assays identified that the average numbers of osteosarcoma
cells that were invading through the Matrigel after treatment
with CBFβ siRNA were significantly lower than the blank
control and the non-specific siRNA groups (Fig. 6h and i).
Taken together, these results demonstrate that CBFβ plays a
role in promoting osteosarcoma cell growth and invasion,
similar to the roles of CDK11 in cancers [9, 11, 13, 15].
High CBFβ expression correlates with CDK11 expression and
contributes to reduced overall survival in osteosarcoma
CBFβ has been shown to contribute to malignancy in
several human solid cancer types [31–34]. We further
examined whether the levels of CDK11 correlated with
the level of CBFβ in tumor cells by using a high-density
tissue microarray (TMA), which included tissues from
73 available characteristics information of osteosarcoma
specimens (Additional file 4: Table S3) [35]. Immunohis-
tochemical analysis showed that CBFβ and CDK11 ex-
pression was quite variable in these samples. Among
the evaluable specimens, 63.3% of CDK11 positive
staining specimens were classified as CDK11-high pa-
tients (63.3%), and 65.6% of CBFβ positive staining speci-
mens were categorized as CBFβ -high patients (Fig. 7a).
These results indicated that the levels of CDK11 and
CBFβ were highly correlated (correlation coefficient R2 =
0.7729, P < 0.0001, Fig. 7b). Kaplan-Meier analysis showed
that osteosarcoma patients had a lower overall survival
rate in the high CDK11 expression group compared with
patients in the low CDK11 expression group (P < 0.0001)
(Fig. 7c). Similarly, higher expression of CBFβ in osteosar-
coma patients also predicted a significantly reduced sur-
vival rate (P = 0.0050) (Fig. 7d). Most importantly, the
CDK11 expressions in 12 metastatic patients were
dramatically higher in their metastatic samples than in
their primary specimens (P = 0.0003) (Fig. 7e). Likewise,
the CBFβ expressions in the samples of the metastatic pa-
tients were significantly higher than in their matched pri-
mary specimens (P = 0.0028) (Fig. 7f). The results above,
coupled with the correlation of high CBFβ levels with
metastatic behavior in breast, prostate, and ovarian cancer
Fig. 5 CDK11p110 upregulates CBFβ expression directly by associating with its promoter. a Schematic representation of potential CDK11 binding
sites in the CBFβ promoter and primer sets (p1, p2, p3, p4) indicating amplified regions encompassing the four primer sites along with the
transcription start site (TSS). Chromatin immunoprecipitations were analyzed using a 2% input of KHOS sample treated with CDK11 siRNA by PCR.
PCR products were only observed with p3 and p4 primer. b ChIP analysis was performed by CDK11 antibodies or 2% input sample and by
measuring enrichment at p3 in human CBFΒ promoter by RT-PCR. The amount of immunoprecipitated DNA by CDK11 antibodies are represented
as ratio of input DNA (1:50) and presented as mean of three independent experiments (n = 3, mean ± SD). *P < 0.05; **P < 0.01, Student’s t-test. c
Electrophoretic mobility shift assay of CDK11- CBFβ binding activity in nuclear extracts from different cell lines. Metastatic cell lines MNNH/HOS
and 143B demonstrated notable high binding activity (lane 3 and 4, purple arrow) compared with KHOS and U-2OS non-metastatic cell lines. d
The formation of CDK11-DNA complexes was determined by incubation with labeled CBFβ. Decreased CDK11 DNA-binding activity was present
in CDK11 siRNA knockdown KHOS and MNNH/HOS cells (purple arrow)
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cells, support the notion that high CBFβ expression in the
primary tumor may contribute to metastatic behavior.
Discussion
In the current study, we have established that CBFβ is a
CDK11 transcriptional target and promotes osteosar-
coma cell growth and metastasis. We utilized global
gene expression profiles after CDK11 knockdown by
siRNA and discovered that CDK11 increases CBFβ
-dependent transcriptional activation in osteosarcoma
cells. Several protein DNA interaction experiments
confirmed CBFβ as a direct transcriptional target of
CDK11p110, but not CDK11p58. High expression of CBFβ
was shown to be associated with poor outcome in osteo-
sarcoma patients. This is the first report demonstrating a
transcriptional regulation of CBFβ by CDK11 and that
CBFβ can be a potential therapeutic target for osteosar-
coma treatment.
Although CDK11 siRNA inhibits widespread transcrip-
tion of a number of genes, CBFβ was the most signifi-
cantly downregulated gene in the analysis. CBFβ, also
known as Polyomavirus Enhancer-Binding Protein 2
Beta Subunit (PEBP2B), can positively regulate transcrip-
tion from the RNA polymerase II promoter. CBFβ plays
an indispensable role in skeletal development and
homeostasis in various skeletal cell types [36–38]. More-
over, CBFβ is essential for invasion and xenograft tumor
growth in some solid tumors, including in breast, pros-
tate, and ovarian cancers [31, 32, 39, 40]. Therefore, fur-
ther validations on the correlation between CDK11 and
CBFβ expression were performed. There are at least
three tiers of evidence that demonstrate that CDK11
Fig. 6 CBFβ contributes to the proliferation and metastatic behavior of osteosarcoma cells. a Confirmation of knockdown of CBFβ protein expression
by Western blotting. CBFβ expressions were abrogated by CBFβ siRNA in a dose-dependent manner. b U-2OS cells were transfected with increasing
concentrations of CBFβ siRNA, and cell proliferation after transfection was determined by MTT assay (n = 3). c U-2OS cells were transfected with CBFβ
siRNA or non-specific siRNA, and cell proliferation after transfection was determined by MTT assay. d KHOS cells were transfected with increasing
concentrations of CBFβ siRNA, and cell proliferation after transfection was determined by MTT assay. e KHOS cells were transfected with CBFβ siRNA or
non-specific siRNA, and cell proliferation after transfection was determined by MTT assay. f Migration distance of U-2OS for each time point and
condition. g Migration distance of KHOS for each time point and condition. h The average number of invasive U-2OS cells among those transfected
with CBFβ siRNA or non-specific siRNA in 24 h. i The average number of invasive KHOS cells among those transfected with CBFβ siRNA or non-specific
siRNA in 24 h. *P < 0.05; **P < 0.01 (comparison of transfected cells with control cells using Student’s t-test)
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mediates CBFβ pathway transcriptional regulation. Firstly,
genome-wide gene profiling identified that CDK11 regu-
lates CBFβ on a transcriptional level and that CBFβ pro-
tein expression depends on CDK11 protein expression.
Secondly, promoter-luciferase assays demonstrated that
CBFβ is regulated by CDK11p110, which is located only in
the nucleus, while CDK11p58 is mainly expressed in the
cytoplasm. Despite data clearly indicating that CDK11p110
interacts with transcriptional proteins and that it is re-
quired for high level in vitro transcription, the exact role
of CDK11p110 in transcription in vivo and the biological
substrates of the kinase remain undetermined [41]. Our
results demonstrated that CDK11p110 induced CBFβ pro-
moter activity in a dose-dependent manner in two
osteosarcoma cell lines. Interestingly, we observed that
CDK11p110, but not CDK11p58, increased CBFβ transcrip-
tional activity. Consistent with this, CBFβ expression is
not cell cycle-regulated and is maintained at high
levels during the cell cycle in osteosarcoma cells [42].
Similarly, CDK11p110 expression is ubiquitous and
constant throughout the cell cycle, while CDK11p58 is
only specifically and transiently expressed during G2-
M phase of the cell cycle. The structural features of
CDK11p110 include its DNA binding area located on
the N-terminus [21, 41, 43, 44]. BindN, a web-based
tool for efficient prediction of DNA binding sites in
amino acid sequences, predicted that 73.3% of DNA-
binding residues are located on the N-terminus of
Fig. 7 High CBFβ expression correlates with CDK11 expression and contributes to metastasis and reduced overall survival in patients. a
Representative images of different immunohistochemical staining intensities of CBFβ and CDK11 staining are shown in osteosarcoma tissues.
CBFΒ and CDK11 immunoreactivity was found mostly in the nucleus of tumor cells. The percentage of cells showing positive nuclear staining for
CBFβ or CDK11 was calculated by reviewing the entire spot (original magnification, 200×). b The correlation coefficient (R2) between CBFβ
expression and CDK11 expression was derived by GraphPad PRISM 5 (correlation coefficient R2 = 0.7729, P < 0.001). c Kaplan-Meier survival curve
of patients with osteosarcoma were subgrouped as either CDK11 low staining (CDK11 staining ≤3) or high staining (CDK11 staining ≥4). d
Kaplan-Meier survival curve of patients with osteosarcoma were subgrouped as either CBFβ low staining (CBFΒ staining ≤3) or high staining
(CBFβ staining ≥4). e Distribution of CDK11 staining scores from the same patients with metastatic and primary specimens. f Distribution of CBFβ
staining scores from the same patients with metastatic and primary specimens
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CDK11p110 [45]. Thirdly, the ChIP assay confirmed that
CBFβ is a direct transcriptional target of CDK11. Increasing
evidence has revealed that the CDK family specifically oc-
cupies the promoters of a subset of genes [46–49]. In one
study, ChIP confirmed CDK8 occupancy on the MYC pro-
moter containing β-catenin/TCF elements [50]. Moreover,
ChIP-seq demonstrated that CDK7 amplified MYCN
mRNA and protein levels by occupying its promoter [51,
52]. Interestingly, CDK11 p110 has been found broadly dis-
tributed on chromatin [22]. In addition, CDK11p110 has
been proven to participate in transcription regulation initi-
ated at an adenosine deaminase (GC)-rich promoter, while
the CBFβ promoter region contains high GC content [20].
In this study, for the first time, we identified CBFβ as a dir-
ect CDK11 target gene and demonstrated that CDK11
binds to the proximal CBFβ promoter by ChIP assay. These
data collectively verified that CBFβ is a sequence-specific
target of CDK11p110 in human osteosarcoma cells. In the
future, it will be of interest to determine whether this
model applies to regulation by CDK11 in other systems.
In addition to demonstrating that CBFβ is a transcrip-
tional target of CDK11, CBFβ showed similar biological
functions to CDK11 in osteosarcoma. CDK11 is essential
for cancer cell growth and invasion [9, 11, 13–16, 34]. In
accordance with previous studies, we demonstrated that
CBFβ is highly expressed in osteosarcoma cell lines, and
especially highly expressed in osteosarcoma metastasis
cell lines. We subsequently demonstrated that CBFβ de-
pletion reduces cell viability, and migration and invasion
activities of metastatic osteosarcoma cells. CDK11p110
expression is ubiquitous and constant throughout the
cell cycle, and CBFβ is maintained at high levels during
the cell cycle in osteosarcoma cells [42]. Aberrant ex-
pression of CBFβ proteins has been linked to patho-
logical events in cancer cells [31, 32, 39]. Expression of
CBFβ is essential for cancer cell invasion and migration,
indicating that CBFβ may have an oncogenic function in
tumor etiology [32, 39, 53–55]. Notably, expression
levels of CDK11 and CBFβ protein are both extremely
low in normal bone osteoblast cells, but are significantly
higher in osteosarcoma cell lines. These may be ex-
plained by the fact that CDK11 and CBFβ possess simi-
lar essential roles in development. CDK11 knockout
mice display an earlier lethality during the blastocyst
stage of embryonic development [56]. Deletion of the
CBFβ subunit revealed impaired bone formation and
caused embryonic lethality [57].
CBFβ is the most frequently mutated and rearranged
gene in human leukemias and plays an important role in
hematologic malignancies [33, 55, 58]. Although no gen-
etic defects have been reported for CBFβ in other types
of human cancers, such as in osteosarcoma, there is a re-
port of multiple CBFβ gene copies detected by FISH in a
single case of granulocytic sarcoma associated with
myeloid leukemia [59]. In line with previous gene profil-
ing, high expression of CBFβ mRNA has been found in
KHOS and U-2OS cell lines, and the expression of CBFβ
is CDK11 expression dependent. Consistent with the cor-
relation of CBFβ and CDK11 on the mRNA level, high
CBFβ protein expression correlates with CDK11 expres-
sion and contributes to diminished overall survival. Fur-
thermore, CDK11 and CBFβ expressions in metastatic
patients were significantly higher than those in their
matched primary specimens, which resulted in lower over-
all survival. Although CBFβ has been shown to play cru-
cial roles in leukemia, the correlation between CBFβ and
clinicopathological features has not been extensively ana-
lyzed in solid tumors. The precise role of CBFβ has not
been fully elucidated, largely due to the complexity of the
transcription factor itself. Since amplification and overex-
pression are generally considered hallmarks of an onco-
gene, CDK11 mediating CBFβ may be oncogenic.
Conclusions
In conclusion, we have taken a genetic approach to under-
standing CDK11 regulated genes in osteosarcoma. A sys-
tematic combination of global gene expression profiling
and DNA-protein assays has led to a wealth of information
about how CDK11 and proteins interact in osteosarcoma
cells. To our knowledge, no similar large-scale genetic ana-
lysis has been carried out on CDK11 or other members of
CDK gene family. Our study identified CBFβ as a direct
transcription target of CDK11p110. Importantly, we have
found a new molecular mechanism that promotes osteosar-
coma cell growth and provided preclinical evidence for the
CDK11p110-mediated CBFβ pathway as a molecular marker
to predict osteosarcoma metastasis risk. These results pro-
vide insights into the use of drugs that target CDK11p110-
CBFβ for human osteosarcoma therapeutics.
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